PUBLICATIONS - Med Inc:
This article was originally published in Clinica
Med Inc, a new book co-authoured by three industry consultants from professional services Price Waterhouse, examines how consolidation is shaping the healthcare industry. It looks at its impact on various healthcare firms including Columbia/HCA Healthcare, MedPartners, and Blue Cross & Blue Shield. Contact Dawn Orlinsky at Med Inc in the US for more information. Tel: +1 212 885 0351.
You may also be interested in...
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.
It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations – and in patient treatment pathways.